A Safety Study of LY2886721 Single Doses in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 single doses, how the body handles the drug, and the drug's effect on the body.

Key facts

Study ID

NCT01133405

Run by

Eli Lilly and Company

People needed

40

Starts

2010-06-01

Expected to finish

2010-10-01

Last updated by the study team

2019-09-16

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men and nonchild-bearing potential women
• 20 years or older
• Body mass index between 18-32 kilograms per square meter (kg/m\^2)

You may not qualify if…

• Taking over-the-counter or prescription medication with the exception of vitamins or minerals or stable doses of thyroid or estrogen hormone replacement
• Smoke more than 10 cigarettes per day

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Beverly Hills, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.